This filing is a routine subsidiary financial disclosure with no immediate catalyst for BCTX. Monitor BriaPro's cash burn and reliance on BriaCell for funding; any future capital needs at BriaPro could lead to dilution or increased related-party obligations.
Price Chart
Executive Summary
BriaCell Therapeutics Corp. disclosed the unaudited financial statements of its subsidiary BriaPro Therapeutics Corp. for the three and nine months ended April 30, 2026. BriaPro remains pre-revenue with a net loss of $712,236 for the nine-month period, an accumulated deficit of $1,892,661, and negative working capital of $1,937,495, with a going concern qualification. This is a routine subsidiary financial disclosure with no direct material impact on BriaCell's stock.
Key Facts
- BriaPro reported no revenue for the three and nine months ended April 30, 2026.
- Net loss for the nine months ended April 30, 2026 was $712,236, compared to $519,804 in the prior-year period.
- Accumulated deficit reached $1,892,661 as of April 30, 2026.
- Negative working capital of $1,937,495 as of April 30, 2026.
- BriaPro is entirely dependent on BriaCell for financing and has a going concern uncertainty.
- On March 31, 2026, BriaPro acquired the sCD80 license from BriaCell for 23,972,589 shares valued at $846,532.
Financial Impact
BriaPro's net loss increased to $712,236 for the nine months ended April 30, 2026, with negative working capital of $1,937,495. No revenue generated.
Risk Factors
- BriaPro's going concern risk due to negative working capital and dependence on BriaCell financing.
- Potential dilution for BCTX shareholders if BriaPro requires additional equity financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-030286 |
| Exhibit: ex99-2.htm | 0001493152-26-030286 |
| Document: form8-k.htm | 0001493152-26-030286 |
| Document: 0001493152-26-030286-index-headers.html | 0001493152-26-030286 |
| Document: 0001493152-26-030286-index.html | 0001493152-26-030286 |
| Document: 0001493152-26-030286.txt | 0001493152-26-030286 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers